Loading clinical trials...
Loading clinical trials...
Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage, in Advance of Delivery/Birth
Conditions
Interventions
Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding
Locations
7
United States
UC Health University of Colorado Hospital
Denver, Colorado, United States
Woman's Hospital
Baton Rouge, Louisiana, United States
Columbia University Irving Medical Center
New York, New York, United States
The Ohio State University
Columbus, Ohio, United States
UPMC Magee Womens Hospital
Pittsburgh, Pennsylvania, United States
Royal Hospital for Women
Randwick, New South Wales, Australia
Start Date
August 6, 2025
Primary Completion Date
June 30, 2026
Completion Date
July 30, 2026
Last Updated
August 8, 2025
NCT04783597
NCT03152058
NCT05763069
NCT05474534
NCT06054412
NCT05782660
Lead Sponsor
Baymatob Operations Pty Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions